We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

AXA Diagnostics Srl

AXA Diagnostics offers a wide range of products, systems and services for laboratory specialists to help diagnose sev... read more Featured Products: More products

Download Mobile App





AXA Diagnostics Showcases SkyLAB752 ELISA Analyzer

By LabMedica International staff writers
Posted on 09 Feb 2017
Print article
Image: The SkyLAB752 ELISA analyzer (Photo courtesy of AXA Diagnostics).
Image: The SkyLAB752 ELISA analyzer (Photo courtesy of AXA Diagnostics).
AXA Diagnostics, part of Dasit Group S.p.A., which owns several companies in the fields of in-vitro diagnostics and life sciences, showcased updates and new applications of the SkyLAB752 system, its platform for ELISA and IFA automation, at MEDLAB 2017 held in Dubai, UAE from February 6-9, 2017.

Italy-based AXA Diagnostics develops, produces, and markets IVD reagents dedicated to autoimmunity diseases and instruments for the automation of all ELISA and IFA testing. The company’s SkyLAB752 fully automated analyzer can process up to 7 ELISA microplates or up to 28 IFA slides per each working session. The SkyLAB752 is equipped with two innovative dispensing systems that work simultaneously and independently, allowing ELISA and IFA assays to be processed simultaneously in the same working session.

The instrument’s architecture is designed to make it adaptable to processing even the greatest workloads. Designed to be easily integrated with a pre-analytical system, the flexibility of its working area allows the SkyLAB 752 to meet the wide requirements of each lab. At MEDLAB 2017, AXA Diagnostics also showcased reagent kits of its autoimmunity product line, which provides a wide choice of analytical techniques for performing both screening and confirmation testing, as well as allows patients’ follow up. This included ELISA reagent kits for the detection of specific auto-antibodies of the main classes (IgG, IgM and IgA) and their combinations, which are indicative of specific pathological conditions. It also included DOT BLOT reagent kits comprising numerous antigenic profiles for the confirmation of systemic autoimmune and organ specific diseases with several specific pathology markers.

New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Ultrasonic Cleaner
UC 300 Series
New
Ultra-Low Temperature Freezer
iUF118-GX

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: Karius Focus BAL is designed to quickly identify the etiology of lung infections and improve diagnostic yield over standard of care testing (Photo courtesy of Karius)

Microbial Cell-Free DNA Test Accurately Identifies Pathogens Causing Pneumonia and Other Lung Infections

Bronchoalveolar lavage (BAL) is a commonly used procedure for diagnosing lung infections, especially in immunocompromised patients. However, standard tests often fail to pinpoint the exact pathogen, leading... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.